Fil LTD Imv Inc. Transaction History

Fil LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$2.12 - $3.24 $424,000 - $648,000	-200,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$2.92 - $4.41 $686,200 - $1.04 Million	-235,000 Reduced 54.02%	200,000 $659,000
Q4 2020 Feb 08, 2021	SELL	$2.9 - $4.4 $1.06 Million - $1.61 Million	-365,000 Reduced 45.63%	435,000 $1.33 Million
Q3 2020 Nov 13, 2020	SELL	$2.87 - $5.95 $2.53 Million - $5.24 Million	-880,000 Reduced 52.38%	800,000 $3.59 Million
Q2 2020 Aug 13, 2020	SELL	$1.52 - $3.63 $547,200 - $1.31 Million	-360,000 Reduced 17.65%	1,680,000 $5.17 Million
Q1 2020 May 14, 2020	SELL	$1.4 - $4.92 $574,560 - $2.02 Million	-410,400 Reduced 16.75%	2,040,000 $3.57 Million
Q4 2019 Feb 07, 2020	SELL	$2.15 - $3.1 $441,180 - $636,120	-205,200 Reduced 7.73%	2,450,400 $7.11 Million
Q2 2019 Aug 13, 2019	SELL	$2.75 - $4.5 $567,600 - $928,800	-206,400 Reduced 7.21%	2,655,600 $7.73 Million
Q1 2019 May 13, 2019	BUY	$3.6 - $5.84 $637,200 - $1.03 Million	177,000 Added 6.59%	2,862,000 $11.5 Million
Q4 2018 Feb 13, 2019	SELL	$4.93 - $6.34 $73,950 - $95,100	-15,000 Reduced 0.56%	2,685,000 $13.5 Million
Q3 2018 Nov 09, 2018	BUY	$4.65 - $5.94 $116,250 - $148,500	25,000 Added 0.93%	2,700,000 $15.8 Million
Q2 2018 Aug 10, 2018	BUY	$4.42 - $7.13 $11.8 Million - $19.1 Million	2,675,000 New	2,675,000 $13.7 Million

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

Stay updated on Fil LTD with notifications on news.